Table 1.

Baseline characteristics of study cohort.

	Fingolimod (N = 271)		Dimethyl fumarate (N = 342)
	N or mean	% or SD	N or mean	% or SD	p value
Disease duration (years, SD)	11.5	7.5	11.1	7.4	0.259
Age (years, SD)	42.5	11.4	45.8	12.2	<0.001
<18 years old	5	1.8%	5	1.5%	0.710
>55 years old	39	14.4%	81	23.7%	0.004
Gender, female	195	72.0%	238	69.6%	0.523
Race					0.186
White	233	86.3%	281	82.2%
Black, African American	4	1.5%	15	4.4%
Other	11	4.1%	13	3.8%
Not available	23	8.1%	33	9.6%
Ethnicity					0.589
Hispanic	15	5.5%	15	4.4%
Non-Hispanic	226	83.4%	284	83.0%
Not available	30	11.1%	43	12.6%
Type of multiple sclerosis					<0.001
Relapsing–remitting	244	90.0%	265	77.5%
Secondary progressive	23	8.5%	54	15.8%
Primary progressive	4	1.5%	23	6.7%
Previous DMTa					<0.001
Interferons	36	13.3%	49	14.3%
Glatiramer acetate	49	18.1%	106	31.0%
Natalizumab	115	42.4%	65	19.0%
Rituximab	1	0.4%	9	2.6%
Fingolimod	N/A	N/A	24	7.0%
Dimethyl fumarate	1	0.4%	N/A	N/A
None	66	24.4%	84	24.6%
Other	3	1.1%	5	1.5%
Mean time between Previous DMT and study drug (SD)	1.05 (N = 205)	1.22	0.75 (N = 258)	1.29	<0.001
Baseline MRI available for review					0.004
Available	235	86.7%	320	93.6%
Unavailable	36	13.3%	22	6.4%
Contrast enhancement on baseline MRI	57 (N = 232)	24.6%	44 (N = 302)	14.6%	0.003
Disease burden on baseline MRI					0.001
Mild	100	36.9%	170	49.7%
Moderate	76	28.0%	94	27.5%
Severe	45	16.6%	29	8.5%
Missing	50	18.5%	49	14.3%

^aWithin six months prior to starting study drug.

DMT: disease-modifying therapy; MRI: magnetic resonance imaging.